Literature DB >> 9684323

Screening of compounds for antimicrosporidial activity in vitro.

E S Didier1, J A Maddry, C D Kwong, L C Green, K F Snowden, J A Shadduck.   

Abstract

Relatively few effective compounds are available for treating microsporidiosis in humans. In this study, several compounds were assayed for activity against Encephalitozoon intestinalis (Cali, Kotler et Orenstein, 1993) and Vittaforma corneae Shadduck, Meccoli, Davis et Font, 1990 in vitro. Of the benzimidazoles tested, albendazole was most effective and the MIC50 values were 8.0 ng/ml and 55.0 ng/ml for E. intestinalis and V. corneae, respectively. Fumagillin and its analogue, TNP-470 were nearly equally effective against both E. intestinalis and V. corneae. The MIC50 values of fumagillin were 0.52 ng/ml and 0.81 ng/ml, and the MIC50 values of TNP-470 were 0.35 ng/ml and 0.38 ng/ml for E. intestinalis and V. corneae, respectively. In addition, 12 of 44 purines and pteridines with putative tubulin binding activity that were synthesized at Southern Research Institute (SRI), inhibited microsporidial replication by more than 50% at concentrations that were not toxic to the host cells. Several chitin synthesis/assembly inhibitors inhibited growth of the microsporidia in vitro but were toxic for the host cells making it difficult to interpret the results. One exception was lufenuron, which caused no significant toxicity to the host cells and expressed approximate MIC50 values of 2.95 micrograms/ml and 6.3 micrograms/ml against E. intestinalis and V. corneae, respectively. These results warrant further studies on albendazole, fumagillin, TNP-470, lufenuron, and the selected SRI purines and pteridines for developing therapeutic strategies for microsporidiosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684323

Source DB:  PubMed          Journal:  Folia Parasitol (Praha)        ISSN: 0015-5683            Impact factor:   2.122


  8 in total

1.  Investigations into microsporidian methionine aminopeptidase type 2: a therapeutic target for microsporidiosis.

Authors:  Hong Zhang; Huan Huang; Ann Cali; Peter M Takvorian; Xiaochuan Feng; Ghou Zhou; Louis M Weiss
Journal:  Folia Parasitol (Praha)       Date:  2005-05       Impact factor: 2.122

Review 2.  Zoonotic potential of the microsporidia.

Authors:  Alexander Mathis; Rainer Weber; Peter Deplazes
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

3.  Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS.

Authors:  A Bicart-Sée; P Massip; M D Linas; A Datry
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 4.  Therapeutic targets for the treatment of microsporidiosis in humans.

Authors:  Bing Han; Louis M Weiss
Journal:  Expert Opin Ther Targets       Date:  2018-11-01       Impact factor: 6.902

5.  Intestinal microsporidiosis in Strasbourg from 2014 to 2016: emergence of an Enterocytozoon bieneusi genotype of Asian origin.

Authors:  Valentin Greigert; Alexander W Pfaff; Ahmed Abou-Bacar; Ermanno Candolfi; Julie Brunet
Journal:  Emerg Microbes Infect       Date:  2018-06-06       Impact factor: 7.163

Review 6.  Current Therapy and Therapeutic Targets for Microsporidiosis.

Authors:  Junhong Wei; Zhihui Fei; Guoqing Pan; Louis M Weiss; Zeyang Zhou
Journal:  Front Microbiol       Date:  2022-03-09       Impact factor: 5.640

7.  High-throughput small molecule screen identifies inhibitors of microsporidia invasion and proliferation in C. elegans.

Authors:  Brandon M Murareanu; Noelle V Antao; Winnie Zhao; Aurore Dubuffet; Hicham El Alaoui; Jessica Knox; Damian C Ekiert; Gira Bhabha; Peter J Roy; Aaron W Reinke
Journal:  Nat Commun       Date:  2022-09-26       Impact factor: 17.694

8.  In Vitro Gene Silencing of the Fish Microsporidian Heterosporis saurida by RNA Interference.

Authors:  Mona Saleh; Gokhlesh Kumar; Abdel-Azeem Abdel-Baki; Mohamed A Dkhil; Mansour El-Matbouli; Saleh Al-Quraishy
Journal:  Nucleic Acid Ther       Date:  2016-05-26       Impact factor: 5.486

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.